Associated Papers
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.
Menzer C et al.
European Journal of Cancer (oxford, England : 1990), 2025
Aggressive nodular melanoma: case report with an unusual BRAF mutation.
El Bardai S et al.
Molecular Biology Reports, 2025
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment.
Amagai R et al.
The Journal of Dermatology, 2025
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS).
Taniguchi H et al.
Cancers, 2025
Synthetic mismatches enable specific CRISPR-Cas12a-based detection of genome-wide SNVs tracked by ARTEMIS.
Kohabir KAV et al.
Cell Reports Methods, 2024
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H et al.
Blood Advances, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S et al.
Cancers, 2024
Hairy cell leukaemia with unusual BRAF mutations.
Maitre E et al.
Journal of Cellular and Molecular Medicine, 2023
Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma.
Xin HY et al.
Jama Network Open, 2023
Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C et al.
Current Treatment Options in Oncology, 2022
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N et al.
Molecular Cancer Research : Mcr, 2021
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
Cheng LY et al.
Scientific Reports, 2021
UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI.
Hsieh YC et al.
Journal of Oncology, 2021
Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P et al.
American Journal of Clinical Dermatology, 2020
BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.
Boyle EM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations.
Giunta EF et al.
Therapeutic Advances in Medical Oncology, 2020
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Menzer C et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
Hou JY et al.
Cancer, 2017
The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.
Kiel C et al.
Elife, 2016
NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A et al.
Diagnostic Pathology, 2015
BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
Ranzani M et al.
Pigment Cell & Melanoma Research, 2015
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
[The detection of activating somatic mutations in gene KRAS using pyrosequencing technique].
Dribnokhodova OP et al.
Klinicheskaia Laboratornaia Diagnostika, 2013
[Polymorphism of ABCB1 and ABCG2 genes encoding drug transporters and their investigation by pyrosequencing].
Dribnokhodova OP et al.
Eksperimental'naia I Klinicheskaia Farmakologiia, 2012